Search results
Showing 1816 to 1830 of 1996 results for nice guidelines
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
Respiratory tract infections (self-limiting): prescribing antibiotics (CG69)
We have withdrawn this guideline and incorporated the relevant recommendations from it into NICE's antimicrobial prescribing guidelines on sinusitis, sore throat, otitis media and cough.
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)
NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.